TEM
Bearish signalScored 2026-10-04 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Research, not advice.
À propos
Tempus AI, Inc.
- Nom
- Tempus AI, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Healthcare Information Services
- Bourse
- NASDAQ
- Capitalisation
- $11.9B
- Employés
- 3,800
- PDG
- Eric Lefkofsky
- Site web
- https://www.tempus.com
- Marché
- BDSXBLLNDGXGHILMNMYGN
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 139 887 titres (~7 023 296,81 $ US)
- Insiders
- Doudna Jennifer AEpstein David RWest NadjaLEFKOFSKY ERIC P
- Total bought
-
—
Avg buy (VWAP, 90d window) $70.00 vs last close $71.98 (+2.8%)
- Total sold
-
$19,978,200
Avg sell (VWAP, 90d window) $54.62 vs last close $71.98 (+31.8%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$10,817,716 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-01
- Liquidity
- Liquid $549,061,014/day · 20d vol
- Last synced
-
2026-10-06 21:10:57
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-25 | Schoenherr Thomas Edward | Sell · S · 10b5-1 | 10,281 | $85.00 | $873,885 | Form 4 |
| 2026-09-22 | LEFKOFSKY ERIC P | Sell · S · 10b5-1 | 160 | $78.86 | $12,618 | Form 4 |
| 2026-09-17 | Bartolucci Ryan M | Sell · S · 10b5-1 | 7,062 | $75.00 | $529,650 | Form 4 |
| 2026-09-17 | LEFKOFSKY ERIC P | Sell · S · 10b5-1 | 645 | $81.09 | $52,303 | Form 4 |
| 2026-09-17 | Polovin Andrew | Sell · S · 10b5-1 | 2,951 | $75.00 | $221,325 | Form 4 |
| 2026-09-16 | Fukushima Ryan | Sell · S | 700 | $70.00 | $49,000 | Form 4 |
| 2026-09-01 | Doudna Jennifer A | Sell · S · 10b5-1 | 676 | $65.55 | $44,312 | Form 4 |
| 2026-09-01 | Epstein David R | Sell · S · 10b5-1 | 250 | $65.55 | $16,388 | Form 4 |
| 2026-09-01 | Fukushima Ryan | Sell · S · 10b5-1 | 1,000 | $64.63 | $64,630 | Form 4 |
| 2026-08-28 | West Nadja | Sell · S · 10b5-1 | 3,000 | $69.00 | $207,000 | Form 4 |
| 2026-08-25 | LEFKOFSKY ERIC P | Sell · S · 10b5-1 | 19,605 | $68.97 | $1,352,157 | Form 4 |
| 2026-08-21 | Fukushima Ryan | Sell · S · 10b5-1 | 14,286 | $70.00 | $1,000,020 | Form 4 |
| 2026-08-21 | Schoenherr Thomas Edward | Buy · S · 10b5-1 | 2,694 | $70.00 | $188,580 | Form 4 |
| 2026-08-21 | Schoenherr Thomas Edward | Sell · S | 2,694 | $70.00 | $188,580 | Form 4 |
| 2026-08-19 | Polovin Andrew | Sell · S · 10b5-1 | 7,927 | $56.00 | $443,912 | Form 4 |
| 2026-08-19 | Rogers James William | Sell · S · 10b5-1 | 26,313 | $60.00 | $1,578,780 | Form 4 |
| 2026-08-19 | Schoenherr Thomas Edward | Sell · S · 10b5-1 | 494 | $61.23 | $30,248 | Form 4 |
| 2026-08-18 | Bartolucci Ryan M | Sell · S | 6,175 | $49.61 | $306,342 | Form 4 |
| 2026-08-18 | Fukushima Ryan | Sell · S | 41,095 | $49.61 | $2,038,723 | Form 4 |
| 2026-08-18 | LEFKOFSKY ERIC P | Sell · S | 132,591 | $49.61 | $6,577,840 | Form 4 |
| 2026-08-18 | Polovin Andrew | Sell · S · 10b5-1 | 22,148 | $49.61 | $1,098,762 | Form 4 |
| 2026-08-18 | Rogers James William | Sell · S · 10b5-1 | 22,529 | $49.61 | $1,117,664 | Form 4 |
| 2026-08-18 | Schoenherr Thomas Edward | Sell · S · 10b5-1 | 9,232 | $49.61 | $458,000 | Form 4 |
| 2026-08-14 | West Nadja | Sell · S · 10b5-1 | 3,000 | $53.90 | $161,700 | Form 4 |
| 2026-08-07 | Fukushima Ryan | Sell · S · 10b5-1 | 20,000 | $50.04 | $1,000,800 | Form 4 |
| 2026-08-03 | Epstein David R | Sell · S · 10b5-1 | 370 | $43.40 | $16,058 | Form 4 |
| 2026-08-03 | Fukushima Ryan | Sell · S · 10b5-1 | 2,562 | $46.94 | $120,260 | Form 4 |
| 2026-07-28 | LEFKOFSKY ERIC P | Sell · S · 10b5-1 | 5,324 | $42.95 | $228,666 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-01-16 | Nancy Pelosi | Purchase | $50,001 - $100,000 |
| 2025-05-09 | Robert P. Bresnahan | Purchase | $1,001 - $15,000 |
| 2025-01-14 | Nancy Pelosi | Purchase | $50,001 - $100,000 |
Signal
Bearish signalScored 2026-10-04 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
TEM presents a mixed picture: while gross margins are improving and the Piper Sandler upgrade adds some positive momentum, the congressional trade signal is significantly undermined by ~$7M in insider selling with zero…
The first sentence of the analysis written for TEM on 2026-10-04 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 3.13 · operating margin -20% — readings disagree
Suggested stop 63.82, nearest stored support minus 0.5 ATR(11.3% under the last close). Reward/risk to the next stored resistance is 0.12. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 62.7% | 55.0% | 53.8% | 40.6% | 32.4% | |
| Ebit Margin | -17.4% | -93.4% | -31.3% | -83.3% | -94.4% | |
| Ebitda Margin | -9.3% | -88.0% | -25.1% | -73.9% | -85.1% | |
| Operating Profit Margin | -19.9% | -99.7% | -36.9% | -82.8% | -94.5% | |
| Pretax Profit Margin | -23.3% | -101.8% | -40.2% | -90.4% | -100.5% | |
| Continuous Operations Profit Margin | -19.3% | -101.8% | -40.3% | -90.4% | -100.5% | |
| Net Profit Margin | -19.3% | -101.8% | -40.3% | -90.4% | -100.5% | |
| Bottom Line Profit Margin | -19.3% | -107.6% | -50.0% | -104.1% | -115.5% | |
| Current Ratio | 3.134 | 2.294 | 1.506 | 2.517 | 3.519 | |
| Quick Ratio | 2.995 | 2.162 | 1.382 | 2.390 | 3.319 | |
| Solvency Ratio | -0.080 | -0.769 | -0.093 | -0.147 | -0.176 | |
| Cash Ratio | 1.624 | 1.171 | 0.713 | 1.739 | 2.419 | |
| Price To Earnings Ratio | -41.879 | -7.339 | -23.266 | -20.431 | -23.000 | |
| Price To Earnings Growth Ratio | 0.604 | -0.044 | 1.910 | -1.625 | -1.318 | |
| Forward Price To Earnings Growth Ratio | 0.604 | -0.044 | 1.910 | -1.625 | -1.318 | |
| Price To Earnings Diluted Ratio | -41.879 | -7.339 | -23.266 | -20.431 | -23.000 | |
| Price To Earnings Diluted Growth Ratio | 0.604 | -0.044 | 1.910 | -1.625 | -1.318 | |
| Price To Book Ratio | 20.944 | 97.148 | -4.490 | -6.056 | -8.468 | |
| Price To Sales Ratio | 8.091 | 7.893 | 11.668 | 21.323 | 26.517 | |
| Price To Free Cash Flow Ratio | -41.940 | -25.919 | -24.927 | -36.646 | -30.559 | |
| Price To Operating Cash Flow Ratio | -47.184 | -28.952 | -28.952 | -40.650 | -32.255 | |
| Debt To Assets Ratio | 0.583 | 0.505 | 0.865 | 0.686 | 0.450 | |
| Debt To Equity Ratio | 2.701 | 8.309 | -0.353 | -0.384 | -0.296 | |
| Debt To Capital Ratio | 0.730 | 0.893 | -0.546 | -0.622 | -0.420 | |
| Long Term Debt To Capital Ratio | 0.716 | 0.885 | -0.482 | -0.527 | -0.419 | |
| Financial Leverage Ratio | 4.630 | 16.438 | -0.408 | -0.559 | -0.658 | |
| Working Capital Turnover Ratio | 2.172 | 2.806 | 2.784 | 1.159 | 0.616 | |
| Operating Cash Flow Ratio | -0.586 | -0.649 | -0.921 | -0.965 | -1.846 | |
| Operating Cash Flow Sales Ratio | -0.171 | -0.273 | -0.403 | -0.525 | -0.822 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.125 | 1.117 | 1.161 | 1.109 | 1.056 | |
| Debt Service Coverage Ratio | -0.951 | -11.382 | -2.851 | -10.821 | -14.458 | |
| Interest Coverage Ratio | -3.599 | -12.881 | -4.184 | -12.124 | -16.051 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.164 | -0.404 | -0.439 | -0.388 | -0.887 | |
| Capital Expenditure Coverage Ratio | -7.999 | -8.546 | -6.193 | -9.153 | -18.015 | |
| Dividend Paid And Capex Coverage Ratio | -7.999 | -6.813 | -5.327 | -7.008 | -12.189 | |
| Dividend Payout Ratio | 0.000 | -0.008 | -0.026 | -0.019 | -0.022 | |
| Enterprise Value Multiple | -92.928 | -9.175 | -48.961 | -29.418 | -30.971 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 62.7% | ▲7.8% | ▲13.8% |
| Ebit Margin | -17.4% | ▲76.0% | ▲46.6% |
| Ebitda Margin | -9.3% | ▲78.7% | ▲47.0% |
| Operating Profit Margin | -19.9% | ▲79.8% | ▲46.9% |
| Pretax Profit Margin | -23.3% | ▲78.4% | ▲47.9% |
| Continuous Operations Profit Margin | -19.3% | ▲82.5% | ▲51.2% |
| Net Profit Margin | -19.3% | ▲82.5% | ▲51.2% |
| Bottom Line Profit Margin | -19.3% | ▲88.4% | ▲60.0% |
| Current Ratio | 3.134 | ▲0.841 | ▲0.540 |
| Quick Ratio | 2.995 | ▲0.834 | ▲0.546 |
| Solvency Ratio | -0.080 | ▲0.689 | ▲0.173 |
| Cash Ratio | 1.624 | ▲0.453 | ▲0.091 |
| Price To Earnings Ratio | -41.879 | ▼-34.540 | ▼-18.696 |
| Price To Earnings Growth Ratio | 0.604 | ▲0.648 | ▲0.699 |
| Forward Price To Earnings Growth Ratio | 0.604 | ▲0.648 | ▲0.699 |
| Price To Earnings Diluted Ratio | -41.879 | ▼-34.540 | ▼-18.696 |
| Price To Earnings Diluted Growth Ratio | 0.604 | ▲0.648 | ▲0.699 |
| Price To Book Ratio | 20.944 | ▼-76.204 | ▲1.128 |
| Price To Sales Ratio | 8.091 | ▲0.198 | ▼-7.007 |
| Price To Free Cash Flow Ratio | -41.940 | ▼-16.021 | ▼-9.942 |
| Price To Operating Cash Flow Ratio | -47.184 | ▼-18.232 | ▼-11.585 |
| Debt To Assets Ratio | 0.583 | ▲0.078 | ▼-0.035 |
| Debt To Equity Ratio | 2.701 | ▼-5.607 | ▲0.706 |
| Debt To Capital Ratio | 0.730 | ▼-0.163 | ▲0.723 |
| Long Term Debt To Capital Ratio | 0.716 | ▼-0.169 | ▲0.681 |
| Financial Leverage Ratio | 4.630 | ▼-11.808 | ▲0.741 |
| Working Capital Turnover Ratio | 2.171 | ▼-0.634 | ▲0.264 |
| Operating Cash Flow Ratio | -0.586 | ▲0.064 | ▲0.408 |
| Operating Cash Flow Sales Ratio | -0.172 | ▲0.101 | ▲0.267 |
| Free Cash Flow Operating Cash Flow Ratio | 1.125 | ▲0.008 | ▲0.011 |
| Debt Service Coverage Ratio | -0.951 | ▲10.431 | ▲7.141 |
| Interest Coverage Ratio | -3.599 | ▲9.282 | ▲6.169 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -0.164 | ▲0.239 | ▲0.292 |
| Capital Expenditure Coverage Ratio | -7.999 | ▲0.547 | ▲1.982 |
| Dividend Paid And Capex Coverage Ratio | -7.999 | ▼-1.185 | ▼-0.132 |
| Dividend Payout Ratio | 0.000 | ▲0.008 | ▲0.015 |
| Enterprise Value Multiple | -92.928 | ▼-83.754 | ▼-50.638 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $10.29B | $5.47B | $6.21B | $6.84B | $6.84B | |
| Enterprise value | $11.01B | $5.60B | $6.53B | $6.97B | $6.80B | |
| EV / Sales | 8.66x | 8.08x | 12.27x | 21.73x | 26.37x | |
| EV / Op. cash flow | -50.50x | -29.62x | -30.46x | -41.42x | -32.07x | |
| EV / Free cash flow | -44.88x | -26.52x | -26.22x | -37.34x | -30.39x | |
| EV / EBITDA | -92.93x | -9.18x | -48.96x | -29.42x | -30.97x | |
| Net debt / EBITDA | -6.09x | -0.21x | -2.42x | -0.55x | 0.18x | |
| Current ratio | 3.13x | 2.29x | 1.51x | 2.52x | 3.52x | |
| Income quality | 0.89x | 0.27x | 1.00x | 0.58x | 0.82x | |
| Graham net-net | -$4 | -$2 | -$11 | -$8 | -$6 | |
| Tax burden | 82.6% | 100.0% | 100.1% | 100.0% | 100.0% | |
| Interest burden | 134.4% | 108.9% | 128.3% | 108.4% | 106.5% | |
| Working capital | $794.8M | $376.5M | $117.7M | $264.4M | $289.2M | |
| Invested capital | $1.77B | $534.4M | $295.2M | $422.6M | $377.8M | |
| Return on assets | -10.8% | -76.2% | -38.0% | -45.9% | -48.8% | |
| Operating ROA | -15.8% | -92.8% | -32.8% | -45.7% | -38.0% | |
| Return on tangible assets | -16.9% | -83.9% | -45.7% | -53.6% | -54.2% | |
| Return on equity | -49.9% | -1252.8% | 15.5% | 25.7% | 32.1% | |
| Return on invested capital | -10.9% | -107.7% | -58.0% | -57.3% | -58.4% | |
| Return on capital employed | -13.3% | -108.8% | -59.2% | -58.1% | -58.5% | |
| Earnings yield | -2.4% | -12.9% | -3.5% | -4.2% | -3.8% | |
| Free cash flow yield | -2.4% | -3.9% | -4.0% | -2.7% | -3.3% | |
| Capex / Op. cash flow | -12.5% | -11.7% | -16.1% | -10.9% | -5.6% | |
| Capex / Depreciation | 26.6% | 59.4% | 103.8% | 60.4% | 49.3% | |
| Capex / Sales | 2.1% | 3.2% | 6.5% | 5.7% | 4.6% | |
| SG&A / Sales | 56.3% | 108.9% | 55.8% | 72.8% | 77.2% | |
| R&D / Sales | 25.1% | 45.7% | 34.9% | 50.6% | 49.8% | |
| Stock comp / Sales | 9.8% | 77.0% | 0.0% | 0.0% | 0.2% | |
| Intangibles / Total assets | 36.3% | 9.2% | 16.9% | 14.3% | 10.0% | |
| Days sales outstanding | 92d | 81d | 65d | 101d | 116d | |
| Days payables outstanding | 63d | 63d | 81d | 88d | 71d | |
| Operating cycle | 132d | 126d | 108d | 144d | 164d | |
| Cash conversion cycle | 69d | 63d | 27d | 56d | 94d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-04 Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference Tempus AI, Inc. (NASDAQ: TEM) today announced that Founder and CEO Eric Lefkofsky will participate in a fireside chat at the Morgan Stanley 24th Annual Global H
- 2026-09-04 Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that Founder and CEO Eric Lefkofsky will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 8:30 a.m. ET in New York City.A live audio webcast of the conversation will be available here.About TempusTempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of t.
- 2026-09-02 Why Moderna''s Cancer Vaccine Matters to Investors Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient''s unique biology.
- 2026-09-02 Tempus AI Director Nadja West Sells 3,000 Shares for $207,000 The disposition involved 3,000 shares executed at $69.00 per share, totaling $207,000 in transaction value on August 28, 2026. The shares traded were equal to 9.00% of the stake held before the filing, leaving the insider with a 0.0183% ownership interest.
- 2026-09-01 Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc''s (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.
- 2026-09-01 Piper Sandler Lifts Tempus AI to Overweight at $76 Tempus AI (TEM) rose 2.46% premarket after Piper Sandler upgraded the stock to Overweight from Neutral and raised its price target to $76 from $56. The firm had
- 2026-08-28 Cathie Wood Invested Roughly $1.4 Billion of Ark Invest''s Flagship ETF in Just 3 Artificial Intelligence (AI) Stocks Wood is known for being a tech-first investor.
- 2026-08-26 Top Performing Leveraged/Inverse ETFs: 08/23/2026 Top Performing Leveraged/Inverse ETFs Last Week These were last week''s top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
- 2026-08-24 What''s Going On With Tempus AI Stock on Monday? Tempus AI Inc (NASDAQ:TEM) stock is trading lower on Monday as the stock is pulling back from an approximately 20% surge over the last week.
- 2026-08-24 Best-Performing Leveraged ETF Areas of Last Week These leveraged ETFs surged last week as biotech, AI, crypto and Bitcoin-linked stocks rallied despite rising Treasury yields.